AR050251A1 - Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto - Google Patents

Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto

Info

Publication number
AR050251A1
AR050251A1 ARP050102198A ARP050102198A AR050251A1 AR 050251 A1 AR050251 A1 AR 050251A1 AR P050102198 A ARP050102198 A AR P050102198A AR P050102198 A ARP050102198 A AR P050102198A AR 050251 A1 AR050251 A1 AR 050251A1
Authority
AR
Argentina
Prior art keywords
alkyl
carbonyl
amino
heterocyclyl
halogen
Prior art date
Application number
ARP050102198A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of AR050251A1 publication Critical patent/AR050251A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Estos compuestos pueden utilizarse para preparar medicamentos, en particular como inhibidores de sintasa de aldosterona. Pueden ser empleados para la prevencion a retardo del avance del estado de hipocalcemia, hipertension, insuficiencia cardíaca congestiva, insuficiencia renal aguda, restinitis y ateroesclerosis, entre otras. Reivindicacion1: Compuestos de la formula general 1 en la cual X es C; Y es C, si Z es C, es también N; Z es C o un enlace; R es hidrogeno, alquilo C1-8, alcoxi C1- 8-alquiloC0-4, halogeno o trifluormetilo; R1 es heterociclilo no saturado-alquilo C0-4, radical que está sin substituir o substituido con 1-4 alquilo C1-8-sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquilo C0-8-carbonil-alquil C1-8-amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8, alcoxi C1-8-carbonilo, heterociclilo o arilo, en donde heterociclilo o arilo están sin substituir o substituidos con 1-4 alquilo C1_8, alquil C1-8-sulfonilo, halogeno, cioano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8.carbonil-amino, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8-amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, caboxi-alquilo C0-4, alcoxilo C1-8-carbonilo; R2 a) es hidrogeno; o b) es alquilo C1-8, cicloalquilo C3-8, halogeno, carboxi-alquilo C1-4, alcoxi C1-4-carbonil-alquilo C1-4, alquil C0-4-carbonilo, aril-alquilo C0-4 o heterociclilo no saturado-alquilo C0-4, radicales que están sin substituir o substituidos con 1-4 alquilo C1-8, alquil C0-8-carbonilo, alquil C1-8 -sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8-amino, cabamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8, alcoxi C1-8-carbonilo, heterociclilo, arilo, en donde heterociclilo o arilo están sin substituir o substituidos con 1-4 alquilo C1-8, alquil C0-8-carbonilo, alquilo C1-8-sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8- amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8 o alcoxi C1-8-carbonilo; n es un numero 0, 1 o 2; y las sales de los mismos, preferentemente las sales faramcéuticamente utiles de los mismos, y su sal, pro droga o compuesto en el cual uno o másátomos están reemplazados por sus isotopos no radioactivos estables, en particular, sal farmacéuticamente util; en los caules si Z es un enlace y R2 es hidrogeno, R1 no es carbazol, benzoimidoazolilo, benzotriazolilo, priridilo, pirimidinilo, pirazinilo o piridazinilo, o si Z es un enlace, R2 es hidrogeno y R1 es un radical heterocíclico que contiene S no saturado, monocíclico, estando estos radicales substituidos con alquil C0-8-carbonilo, ciano, arilo o heterociclilo.
ARP050102198A 2004-05-28 2005-05-27 Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto AR050251A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH9162004 2004-05-28
CH11572004 2004-07-09

Publications (1)

Publication Number Publication Date
AR050251A1 true AR050251A1 (es) 2006-10-11

Family

ID=34993240

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102198A AR050251A1 (es) 2004-05-28 2005-05-27 Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto

Country Status (11)

Country Link
US (1) US20080076794A1 (es)
EP (1) EP1748986B1 (es)
JP (1) JP2008500999A (es)
AR (1) AR050251A1 (es)
AT (1) ATE490241T1 (es)
BR (1) BRPI0510412A (es)
CA (1) CA2568164A1 (es)
DE (1) DE602005025110D1 (es)
IL (1) IL179409A0 (es)
TW (1) TW200608978A (es)
WO (1) WO2005118541A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568159A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
ME01923B (me) 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
ES2683350T3 (es) 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
MA38330B1 (fr) 2013-02-14 2016-09-30 Novartis Ag Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
JP2018507187A (ja) 2015-01-23 2018-03-15 ノバルティス アーゲー 改善された半減期を有する合成アペリン脂肪酸コンジュゲート
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN113166101A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887388A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859691A (en) * 1987-07-08 1989-08-22 Ciba-Geigy Corporation Certain 1,2-benzisoxazole derivatives
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
JP3170273B2 (ja) * 1989-06-05 2001-05-28 第一製薬株式会社 縮合トリアジン誘導体及びその中間体
IL94592A (en) * 1989-06-05 1994-07-31 Daiichi Seiyaku Co History Transformed by piperidinoalkyl of 1,2,4-triazolone and 1,3,5-triazinedione in compressed bicycles, their preparation and pharmaceutical preparations containing or
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
AU668708B2 (en) * 1992-01-27 1996-05-16 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
EP1311192A4 (en) * 1999-10-22 2006-03-01 Glaxo Group Ltd -G- (IN VIVO) IMAGING
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds

Also Published As

Publication number Publication date
WO2005118541A2 (en) 2005-12-15
TW200608978A (en) 2006-03-16
US20080076794A1 (en) 2008-03-27
BRPI0510412A (pt) 2007-10-23
CA2568164A1 (en) 2005-12-15
WO2005118541A3 (en) 2006-02-02
ATE490241T1 (de) 2010-12-15
IL179409A0 (en) 2007-05-15
JP2008500999A (ja) 2008-01-17
EP1748986B1 (en) 2010-12-01
EP1748986A2 (en) 2007-02-07
DE602005025110D1 (de) 2011-01-13

Similar Documents

Publication Publication Date Title
AR050251A1 (es) Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto
AR047706A1 (es) Inhibidores de polimerasa viral
AR065901A1 (es) Derivados de pirrolipirimidina
AR065280A1 (es) Agentes antiparasitarios
AR040076A1 (es) Derivados de piridazin-3(2h)-ona
AR058006A1 (es) Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos
AR061737A1 (es) Compuestos derivados de pirimidina, un peoceso para su preparacion y composiciones farmaceuticas que los contienen
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
AR053778A1 (es) Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR100817A1 (es) Pirazoles y tetrazoles sustituidos con halógeno
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR066691A1 (es) Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR045752A1 (es) Derivados de quinazolina que poseen actividad antitumoral
AR047367A1 (es) Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure